Approval of New Dispensing Facility
1 July 2026
MedPal AI plc
("MedPal AI") or the "Company")
New Dispensing Facility in Runcorn
Opening of Sarus Court - the Group's largest robotic dispensing facility to date
NHS approval received for new 23,000 sq. ft location; designed capacity of over 10,000 prescription orders per day.
MedPal AI plc, the AI-powered integrated digital health and pharmacy group, is pleased to announce the opening of its new robotic pharmacy dispensing and distribution facility at Sarus Court, Runcorn ("Sarus Court") together with receipt of NHS approval for the new location.
Sarus Court will be the Company's largest pharmacy robotic distribution facility to date and is expected to provide approximately 23,000 sq ft of operational capacity when fully completed. It will replace the existing pharmacy distribution facility in Runcorn, as set out in the Company's announcement of 29 April 2026, and operate in addition to the Company's facility in Swaffham. The facility is being commissioned in phases and will, from this month, process more than 2,000 prescription items per day, with infrastructure designed to support throughput of over 10,000 prescription items per day once fully completed and operational.
The new facility benefits from over £1 million of investment in robotics, automation and MedPal AI's proprietary pharmacy technology stack. The Board of MedPal AI believes this investment, combined with Sarus Court's scale, workflow design and direct-to-patient operating model, positions the facility to become one of the most sophisticated and lowest-cost pharmacy dispensing platforms in the UK at scale.
At full designed capacity, Sarus Court would be capable of processing more than 300,000 prescription items per month. For comparison, the latest public PharmData leaderboard reviewed by the Company shows Well.co.uk at 142,011 items and Boots at 87,992 items for February 2026. Sarus Court's planned capacity would therefore be more than twice the Well.co.uk monthly item level and more than three times the Boots monthly item level shown on that leaderboard.
The scale of Sarus Court also compares favourably with other major investments in UK pharmacy automation. Boots announced in September 2025 the opening of its first Regional Dispensing Hub in Basingstoke, a 20,000 sq ft automated facility supporting 150 stores in the South of England. At 23,000 sq ft when fully completed, Sarus Court is expected to be larger by footprint.
Images of the robotic dispensing and packing facilities and the exterior of Sarus Court in Runcorn.
Jason Drummond, Chief Executive Officer of MedPal AI, commented:
"Sarus Court is a major statement of intent for MedPal AI. It is our largest robotic pharmacy distribution facility to date, NHS-approved for the new location, and designed to give us the operational headroom to scale from approximately 2,000 prescription items per day today to more than 10,000 items per day when fully completed.
"We have invested over £1 million in robotics, automation and our pharmacy technology stack to create a platform that we believe can become one of the most sophisticated and lowest-cost dispensing operations in the UK.
"The size and capacity of Sarus Court place MedPal AI firmly among the most ambitious technology-led pharmacy operators in the UK. At 23,000 sq ft when fully completed, the facility is larger by footprint than Boots' recently opened 20,000 sq ft Basingstoke dispensing hub, while its designed item capacity is significantly above the monthly item levels currently reported by leading individual Well and Boots pharmacy entries on PharmData.
"This facility gives MedPal AI the scale, automation and resilience required to support the next phase of our growth across NHS dispensing, private prescriptions, AI-enabled patient engagement and direct-to-patient pharmacy fulfilment."
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018). The Directors of the Company are responsible for the contents of this announcement
Enquiries:
MedPal AI plc
Jason Drummond, Chief Executive Officer
Via Square1 Consulting
Cairn Financial Advisers LLP
Louise O'Driscoll/Jo Turner
+44 (0) 20 7213 0880
Oak Securities (a trading name of Merlin Partners LLP)
Tim Dainton/Calvin Man
+44 (0) 20 3973 3678
Clear Capital Markets Limited
Bob Roberts
+44 (0) 20 3869 6080
Square1 Consulting
David Bick
+44 (0) 20 7929 5599
+44 (0) 7831 381201
About MedPal AI
MedPal AI is a UK-based digital health company building the MedPal Health OS - a vertically integrated, closed-loop platform spanning AI wellness, clinical services, and automated pharmacy fulfilment. Its core app aggregates data from over 100 wearable devices and health apps (including Apple Health, Fitbit, Garmin, and Whoop) into a unified health profile, offering personalised, non-clinical lifestyle guidance through its AI wellness coach and acting as the consumer front door to the Company's clinical and pharmacy services.
Through its wholly owned subsidiary MedPal Limited, the Company operates a 24/7 AI-powered automated pharmacy distribution centre, providing nationwide NHS and private prescription services. The facility leverages BD Rowa VMAX robotic dispensing technology integrated with AI triage to deliver rapid, cost-effective medication fulfilment with same-day and next-day delivery capabilities.
MedPal AI has a partnership agreement with Epassi UK Limited, which will, for a limited time, grant exclusive, zero-cost access to the MedPal AI app across Epassi's network of 11M+ employees at major firms. The Company's LEI is 984500EDP8B0A14CBA61.
Forward Looking Statements
This announcement contains forward-looking statements, which are based on the Company's current expectations, intentions and projections regarding its future performance, anticipated events or trends and other matters that are not historical facts. Forward-looking statements are often identified by words such as "believes", "expects", "intends", "may", "will", "should", "could", "plans", "targets", "aims" or similar expressions. Such statements are subject to risks, assumptions and uncertainties and actual results, performance or events may differ materially from those expressed or implied by them. The Company undertakes no obligation to update any forward-looking statements, except as required by applicable law, the AIM Rules for Companies, the UK Market Abuse Regulation or other applicable regulation.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDSTRWPUGWQUPQGQU
